From the Business/Higher Education Round Table (Australia):
The Seeds of Transition: Initiatives for the 2020 Economy and Beyond
A repositioned economy based on structural change enabling knowledge/IP translation and not restricted by geography is an outcome that will serve Australia well as we move further into the 21st century. And so it is that the contributors for this edition of the B/HERT News bring a focus to initiatives that will be a part of this journey.
B/HERT News #35 [PDF]
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.
Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.